Tequila is a distilled beverage made from the blue agave plant that offers many health benefits such as being low in calories and carbohydrates. It also contains flavonoids and phenolic compounds that act as antioxidants. Tequila is used for social gatherings and is available in multiple varieties like blanco, reposado, añejo based on aging time. The global Tequila Market is estimated to be valued at US$ 434.01 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Premiumization has been a key trend in the tequila market over the recent years. Premium and super premium tequila brands are gaining more traction across globally. Consumers are increasingly opting for higher quality and more expensive variants of tequila. Premium brands offer artisanal craft tequila which is handcrafted and made with traditional methods unlike mass produced variants. They also offer differentiated packaging and marketing strategies targeted at affluent consumers who are willing to pay premium prices. This shift towards premiumization is expected to drive higher profit margins and accelerate market growth over the forecast period.
Segment Analysis
The global tequila market is segmented by product type, price point, distribution channel, and region. By product type, the repojo segment dominates the market and is expected to continue its dominance over the forecast period. Repojo is gaining popularity due to its premium quality and taste as compared to other product types.
Key Takeaways
The Global Tequila Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2024 is estimated to be US$ 434.01 Mn.
Regional analysis: The North American region currently dominates the tequila market and is expected to continue doing so owing to the rising popularity of tequila drinks in cocktail recipes and parties. Mexico is also one of the fastest growing markets for tequila due to availability of agave plants required for production and a large Hispanic population demanding the native drink.
Key players operating in the tequila market are ABB Ltd., Hitachi Ltd, Emerson Electric Co., Alstom, International Business Machines Corporation, Honeywell International Inc., Schneider Electric, Rockwell Automation, Inc., JFE Engineering Corporation, ICONICS, Inc., Mitsubishi Electric Corporation, and others. These players are focusing on new product launches and expansion strategies to gain a competitive advantage in the market.
For More Insights, Read: https://www.newswirestats.com/tequila-market-trends-growth-and-regional-outlook-2023-2030/
The global tequila market size is expected to reach USD 14.70 billion by 2028, exhibiting a CAGR of 5.8% during the forecast period.
The growing trend towards artisanal spirits coupled with high alcohol consumption among consumers will push the growth of the tequila market in the forthcoming years, states Fortune Business Insights, in a report, titled “Tequila Market Size, Share & COVID-19 Impact Analysis, By Type (Blanco, Reposado, Anejo, and Others), Grade (Value, Premium, High-end Premium, and Super Premium), Distribution Channel (On-trade and Off-trade), and Regional Forecast, 2021 – 2028.” The market size stood at USD 9.41 billion in 2020.
Flourishing E-commerce Channels to Stabilize Market during PandemicThe COVID-19 pandemic caused massive disruption in the food and beverage industry's supply chain because of restrictions on transportation and logistics.
List of the Leading Companies Profiled in the Global Tequila Market are:Diageo Plc (London, United Kingdom)Tequila Ocho (United States)Bacardi & Company Ltd. (Hamilton, Bermuda)Vault Fine Spirits Pvt.
Ltd. (Mumbai, India)Charbay Distillery (United States)Tequila Fortaleza (Mexico)Proximo Spirits, Inc. (New Jersey, United States)Brown-Forman Corporation (Kentucky, United States)Pernod Ricard S.A. (Paris, France)Casa Aceves Spirits (Mexico) The escalation in Cocktail Culture to Strengthen Tequila BusinessBroad-spectrum of people indulging in cocktails such as Paloma, El Diablo, and others can offer immense growth opportunities in the market.
Key Market Segments:Based on type, the market is divided into blanco, reposado, anejo, and others.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
